CUE Stock Overview
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders.
Cue Biopharma, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.24|
|52 Week High||US$18.42|
|52 Week Low||US$2.18|
|1 Month Change||4.85%|
|3 Month Change||13.29%|
|1 Year Change||-75.02%|
|3 Year Change||-57.98%|
|5 Year Change||n/a|
|Change since IPO||-72.14%|
Recent News & Updates
Cue Biopharma shares rise ~10% on FDA fast track nod for head and neck cancer drug
Cue Biopharma (NASDAQ:CUE) on Tuesday said it had got a fast track designation from the U.S. FDA for its drug candidate CUE-101 for the treatment of head and neck cancer associated with human papilloma virus. CUE stock jumped 9.6% to $2.62 in early trading. The designation was for CUE-101 as a monotherapy and in combination with Merck's (MRK) Keytruda for the treatment of human papilloma virus recurrent/metastatic head and neck squamous cell carcinoma. The FDA's Fast Track approval is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. "To date in its Phase 1b clinical trials, CUE-101 has demonstrated a favorable tolerability profile and single-agent anti-tumor activity in monotherapy as well as encouraging anti-tumor clinical activity in combination with (Keytruda)," CUE senior vice president of clinical development Matteo Levisetti said in a statement.
Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
News Flash: 4 Analysts Think Cue Biopharma, Inc. (NASDAQ:CUE) Earnings Are Under Threat
The analysts covering Cue Biopharma, Inc. ( NASDAQ:CUE ) delivered a dose of negativity to shareholders today, by...
|CUE||US Biotechs||US Market|
Return vs Industry: CUE underperformed the US Biotechs industry which returned -20.8% over the past year.
Return vs Market: CUE underperformed the US Market which returned -18.2% over the past year.
|CUE Average Weekly Movement||13.4%|
|Biotechs Industry Average Movement||11.2%|
|Market Average Movement||7.0%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: CUE is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: CUE's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases.
Cue Biopharma, Inc. Fundamentals Summary
|CUE fundamental statistics|
Is CUE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CUE income statement (TTM)|
|Cost of Revenue||US$42.44m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.38|
|Net Profit Margin||-418.28%|
How did CUE perform over the long term?See historical performance and comparison